Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.
|Original language||English (US)|
|Journal||Clinical orthopaedics and related research|
|Issue number||415 SUPPL.|
|Publication status||Published - Oct 2003|
All Science Journal Classification (ASJC) codes
- Orthopedics and Sports Medicine